Background: The mortality figures for lupus have decreased from 50% 4-year survival (1950s) to 85% survival now. However it causes a host of morbidities. Using the BILAG activity categories this talk focuses on the key consequences of non-fatal lupus. Discussion: In the constitutional system fatigue remains a major problem affecting > 80% of patients. Its cause is complex invariably a combination of disease activity, anaemia (several possible causes), depression, hypothyroidism and fibromyalgia. Although some of these factors are correctable, fatigue remains challenging. Dermatologically alopecia is found in 25-40% of patients with scarring a major concern in 10-15% of patients who develop it. Alopecia reflects disease activity and is often improved by more aggressive treatment but scarring is permanent. In the central nervous system, psychosis is devastating causing gross impairment in reality and disordered thinking. It is often accompanied by other aspects of active lupus. It occurs in 2% of patients, usually within the first two years of disease onset. The keys to successful management are immunosuppression, anti-psychotic drugs and time -this does not get better quickly. In the musculoskeletal systemic erosive arthritis (RUPUS) is present in 5%. Some patients move from SLE to rheumatoid arthritis and treating with methotrexate and, rarely, TNF alpha-blocking drugs can be very helpful but the latter have a predisposition to induce DNA antibodies; not necessarily the best thing to happen in a lupus patient. In the cardiovascular system, pulmonary hypertension has a prevalence of approximately 15% (using > 30mm Hg as a cut-off for right ventricular systolic pressure). The diagnosis is best made by Doppler echocardiography. Ventilation profusion scans are important to exclude multiple pulmonary emboli. Once considered a fatal condition, its treatment has been revolutionised by the advent of continuous intravenous prostacyclin and its analogues; if severe anticoagulation is recommended. Gastrointestinal manifestations in lupus are common and abdominal pain is divided into acute and common -the former much more likely to be associated with active lupus elsewhere and the latter with many non-lupus related problems. In the kidneys renal failure is genetically more likely to occur in black compared to Caucasian or South Asian patients but in any ethnicity, poor adherence remains a considerable influence upon its development. Effective dialysis and transplantation has hugely benefited this group. Haematologically thrombocytopenia may be acute and dramatic (often associated with anti-platelet antibodies) or chronic persistent (linked to antiphospholipid antibodies). For the more acute patients, rituximab and eltrombopag have proven effective. Ophthalmologically retinal vasculitis leading to blindness is recognised but mercifully rare. Finally other more classic long-term complications of lupus including osteoporosis, premature atherosclerosis and a slight increase in the risk of non-Hodgkin's lymphoma are other important factors to be considered. Disclosures: The author has declared no conflicts of interest.
I053 THE LONG-TERM COMPLICATIONS OF NON-FATAL RHEUMATOID ARTHRITIS
Peter Taylor 1 1 Rheumatology, University of Oxford, Oxford, UNITED KINGDOM People with rheumatic arthritis have an increased likelihood of comorbidities compared to the general population. Some of the common comorbidities observed in this population include cardiovascular disease, infection, depression, osteoporosis and certain malignancies. This high prevalence has been attributed to chronic inflammation, traditional cardiovascular risk factors, and genetics and to the medications used to treat these conditions. The presence of comorbidity has a major influence on disease outcome, including quality of life, physical function and mortality. In addition, comorbidities add to the complexity of achieving treatment targets and increase the utilisation and cost of care. The last two decades have witnessed significant improvements in the early recognition of rheumatoid arthritis with the publication of the 2010 EULAR/ACR classification criteria, coupled to the understanding of the importance of early therapeutic intervention and implementation of a tight control management paradigm. In addition, advances in the understanding of the pathobiology of rheumatoid arthritis, with concurrent progress in protein and small molecular engineering, have heralded the era of targeted therapies. Collectively, these advances have facilitated a greatly improved long-term outlook for patients presenting with rheumatoid arthritis with a corresponding reduction in the incidence of certain co-morbidities associated with a persistent systemic inflammatory response. However, the management of comorbidities remains a challenge. The time constraints for consultations in general rheumatology clinics, where the focus is on the index disease, coupled with a lack of disease specific practical guidelines on managing comorbidities, are common barriers to effective management of comorbid conditions in this population. With an expanding pharmacotherapeutic armamentarium comprising many targeted therapies, recognition of established co-morbidities is of great practical importance with respect to treatment choice, effectiveness and healthcare costs. Measurement and documentation of outcomes in both the clinical setting and in research should include the impact of comorbidities on overall quality of life for the patient. Validated screening tools are available for detection of comorbidity and can usefully be incorporated into clinical care, particularly at annual review clinics. Rheumatologists have a vital role to play in preventing, detecting and managing comorbidities, as well as coordinating care among other healthcare providers. There is a case to be made that the development of care plans encompassing a more holistic approach that incorporates comorbidities, rather than focussing on a single disease orientated model, will greatly improve overall patient survival and quality of life in rheumatic diseases. Disclosures: P.T. consultancies; UCB, BMS, Pfizer, AbbVie, Sandoz, Biogen, Lilly, Celgene, Novartis, Roche, GSK. Grants/research support; Galapagos, Lilly, UCB, Celgene, Janssen.
I054 THE LONG-TERM COMPLICATIONS OF NON-FATAL INFLAMMATORY MUSCLE DISEASE
Jiri Vencovsky 1 1 Institute of Rheumatology, Charles University in Prague, Prague, CZECH REPUBLIC Mortality is increased in patients with idiopathic inflammatory myopathies (IIMs) and the overall hazard ratio of death is almost four times higher in comparison with general population. Although some patients may have monophasic illness a majority has relapsingremitting course or chronic progressive illness lasting for many years. The long-term complications can arise from the disease activity itself or may be a consequence of glucocorticoid and/or immunosuppressive treatment. Disease causes damage to involved muscles manifesting as atrophy and fatty replacement, best seen on MR images. In some patients muscle weakness persists despite absence of apparent disease activity or muscle damage. This may be associated with maintenance glucocorticoid treatment leading to steroid myopathy or increased insulin resistance, but occasionally this persisting muscle impairment remains unexplained. Changed expression of genes involved in skeletal muscle tissue remodelling as well as altered expression of genes associated with lipid uptake, lipolysis, and lipid accumulation was reported recently in these patients and attributed to preceding conventional immunosuppressive treatment or disease process. The worst functional outcomes in terms of muscle involvement are often seen in patients with anti-SRP antibodies and in inclusion body myositis. These patients are notoriously non-responsive to most currently available drugs. Some patients have long lasting extramuscular manifestations, such as arthritis or alveolitis, particularly those with antisynthetase syndrome. A cross-sectional analysis found presence of arthritis in almost 50% of IIMs patients suggesting that this is a frequent manifestation in established disease. In some patients it may be resistant to treatment requiring use of biologicals such as rituximab. This drug is also used with good effect in patients with interstitial lung disease (ILD). ILD is found in 25-70% of patients with IIMs and represents a major risk factor for morbidity. Few patients may develop pulmonary arterial hypertension which is associated with poor quality of life and shorter survival. Soft tissue calcifications can be disabling and occur most commonly in juvenile DM with anti-NXP-2 antibodies. This antibody is rarer in adults, but the presence of anti-NXP-2 in these patients maintains the association with calcinosis. When calcinosis develops it is often resistant to treatment and can be rather disabling complication. Dysphagia is a frequent symptom in IIMs and is due to active inflammation of upper esophagus muscles. Treatment resistant dysphagia can be a consequence of muscle fibrosis and may require cricopharyngeal myotomy to alleviate symptoms. The most commonly encountered side effects of treatment include osteoporosis and bone fractures, osteonecrosis, serious 
